Evidence map›Paper›PMID 37435281›Full record

ArticleNorthern clinics of Istanbul2023

Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder.

Zerrin Karaaslan, Vuslat Yilmaz, Hande Yuceer, Elif Sanli, Halil Ibrahim Akcay, Murat Kurtuncu, Recai Turkoglu, Erdem Tuzun

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Northern clinics of Istanbul, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zerrin KaraaslanDepartment of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
Vuslat YilmazDepartment of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
Hande YuceerDepartment of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
Elif SanliDepartment of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
Halil Ibrahim AkcayDepartment of Neurology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye.
Murat KurtuncuDepartment of Neurology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye.
Recai TurkogluDepartment of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkiye.
Erdem TuzunDepartment of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
HUN-REN Institute of Experimental Medicine · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response.

methodsCXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls.

resultsFingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients.

conclusionFingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.

Indexed as

C-X-C motif chemokine 5fingolimodmultiple sclerosisneuromyelitis optica spectrum disorder

Identifiers

PMID37435281
PMCPMC10331241
OpenAlexW4285128840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.